| Literature DB >> 35780086 |
Tomohiro Mitoma1, Kei Hayata2, Satomi Yokohata2, Akiko Ohira2, Chiaki Kashino2, Satoe Kirino2, Kazumasa Tani2, Jota Maki2, Eriko Eto2, Hisashi Masuyama2.
Abstract
BACKGROUND: Cases of uterine wall thinning and placental abnormalities complicated with systemic lupus erythematosus (SLE) during pregnancy have been reported in Asian countries for ten years. Long-term steroid use can cause muscle degeneration, but the mechanism of myometrium thinning was not known. Through the review of published articles, this report is the first review of cases to discuss the pathogenesis and clinical features of thinned myometrium and placenta accreta spectrum (PAS) in pregnant patients with SLE. CASEEntities:
Keywords: Estrogen; Lupus; Myometrium; Placenta accreta spectrum; Uterine atony
Mesh:
Substances:
Year: 2022 PMID: 35780086 PMCID: PMC9250175 DOI: 10.1186/s12884-022-04864-z
Source DB: PubMed Journal: BMC Pregnancy Childbirth ISSN: 1471-2393 Impact factor: 3.105
Fig. 1Ultrasonography image. a the placenta was at anterior to bottom of the uterus without clear borderline of the placenta and the muscle layer at the 28th gestational week. b Thickened placenta with large lacunae at the bottom of the uterus at 39th gestational week
Fig. 2Photo image. a Anterior surface of the uterus with engorged vessels at the time of laparotomy. b Atonic uterus lifted out of the pelvic cavity after bleeding control
Fig. 3a Longitudinal image of the uterus and placenta after hysterectomy. Placenta (black arrow) attached to extreme thinned uterine wall (white arrow). b Gross photography of the uterus, which incised the anterior wall, and the placenta was attached to the widespread entire uterine wall
Case reports of SLE during pregnancy with uterine wall thinning and PAS
| Author,year | Age(y) | Parity | PSL duration(y) | PSL use during pregnancy | Risk factors of PAS | Obstetric complication | GA at labror(wk) | Induction labor | Delivery | Treatment | Amount of blood loss(ml) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Noh JJ et al., 2013 [ | 36 | 0 | 19 | Yes | IVF | Rupture uterus | 23 | None | CS | Hysterectomy | NS |
| Tokushige Y et al., 2017 [ | 35 | 0 | 5 | Yes | IVF | GH | 39 | Yes (Oxytocin) | CS | Hysterectomy | 4500 |
| Tomimatsu T et al., 2021 [ | 32 | 0 | 8 | Yes | IVF | PE | 35 | Yes (Oxytocin) | CS | Hysterectomy | 2200 |
| Mittal N et al., 2018 [ | 36 | 2 | 9 | Yes | Placenta previa | Placenta previa | 36 | None | CS | Hysterectomy | 6000 |
| Kim HM et al., 2020 [ | 33 | 0 | 10 | Yes | None | Rupture uterus | 34 | None | CS | Hysterectomy | NS |
| Kim HM et al., 2020 [ | 30 | 0 | 8 | NS | None | None | 38 | None | CS | Hysterectomy | NS |
| Inoue A et al., 2020 [ | 37 | 0 | 19 | Yes | IVF | NRFS,FGR | 36 | None | CS | Hysterectomy | 5860 |
| Our case | 29 | 0 | 2 | none | none | none | 39 | Yes (Oxytocin) | CS | Hysterectomy | 5400 |
Abbreviations: PSL predonisolone;GA,gestational age, IVF in vitro fertilization, CS cesarean section, GH gestational hypertension, PE preeclampsia, NRFS non-reassuring fetal status, FGR fetal growth restriction, NS not stated, SLE systemic lupus erythematosus, PAS placenta accrete spectrum